Related Experiment Video
Updated: Aug 28, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Epidemiology and management of HIV-2
Serge Paul Eholié1, Charlotte Charpentier2, Zelica Diallo1
1Faculty of Health Sciences, University Felix Houphouët-Boigny, Abidjan, Côte d'Ivoire; Centre de Recherche en Maladies Infectieuses et Pathologies Associées, Treichville University Teaching Hospital, Abidjan, Côte d'Ivoire.
Abstract:
HIV-2 remains a neglected component of the global HIV epidemic, predominantly affecting west Africa but also present in Europe and other regions through historical and migratory links. Although generally characterised by lower transmissibility and slower disease progression than HIV-1, HIV-2 poses distinct diagnostic, therapeutic, and programmatic challenges. Research, implementation, and advocacy efforts aimed at reducing HIV-2 infection must account for the limitations of available typing tools, the restricted access to validated viral load assays, the virus' intrinsic resistance to certain antiretroviral drug classes, and the gaps in retention in care that hinder progress towards global treatment targets. Strengthening collaborative research, improving diagnostic capacity, and integrating HIV-2 into broader HIV policy frameworks are essential to optimise patient outcomes and to advance the global HIV response.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Genital Herpes
Smallpox
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Cryptococcal Meningitis

